Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Celularity ( (CELU) ) has shared an update.
On December 19, 2025, Celularity Inc. entered into senior secured note and convertible note financings with investor Philip A. Barach, receiving $10 million in gross proceeds at closing and structuring commitments for up to an additional $2 million, subject to conditions and the investor’s election. The package comprises a $7 million senior secured term loan backed by a first‑priority lien on substantially all company assets and a secured convertible note facility of up to $5 million, including a $3 million initial note convertible into Class A common stock at $1.66 per share and additional tranches available to both the lead investor and potential participation purchasers, alongside warrants to purchase 3,707,657 shares at $2.00 per share from June 19, 2026 to December 19, 2030. The notes rank pari passu, include investor-favorable participation and “most favored nation” protections for future financings, and grant the investor a board observer right, collectively strengthening Celularity’s near-term liquidity while giving the investor significant economic upside and governance visibility. Management said the December 22, 2025 closing of these privately placed, SEC-registration-exempt securities is intended to support ongoing operations and strategic initiatives as the company sharpens its focus on leveraging its placenta-derived platform in longevity, healthy aging and performance optimization, with implications for a potential reshaping of its portfolio and corporate strategy to drive longer-term value for patients and shareholders.
The most recent analyst rating on (CELU) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Underperform.
Celularity’s overall stock score is primarily impacted by its financial instability, with high leverage and ongoing losses. Technical indicators suggest bearish momentum, and valuation metrics are weak due to negative earnings. Corporate events add further risk with shareholder resistance and regulatory challenges.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and aging‑related cellular medicine company that develops, manufactures and commercializes advanced biomaterial products and allogeneic and autologous cell therapies derived from postpartum placentas. The company targets significant unmet global needs in age-related and degenerative diseases by focusing on fundamental aging mechanisms such as cellular senescence, chronic inflammation and tissue degeneration, and is positioning its placental-derived platform within the emerging longevity and healthy aging market.
Average Trading Volume: 115,867
Technical Sentiment Signal: Sell
Current Market Cap: $41.08M
For an in-depth examination of CELU stock, go to TipRanks’ Overview page.